India's vaccine industry, the world's third largest by volume, is targeting over USD 3 billion in 2026, driven by biosimilars, government UIP expansions, and BioE3 policies boosting local production.
Globally, the market reaches USD 67-96 billion this year with 6-10% growth fuelled by mRNA vaccines for adults and pandemic readiness. Include AI-powered cold chains for better storage, faster manufacturing via PLI funds for APIs, and efforts to cut hesitancy through awareness and compensation schemes. Despite factory and regulatory hurdles, these steps position India as a key player amid rising demand for multi-disease shots.